Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.
Status:
Recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
A phase IIIb, open-label, single arm study to evaluate the efficacy and safety of
luspatercept in patients with lower-risk MDS and ring-sideroblastic phenotype (MDS-RS)